Get the Stockscreener App
0.9349
1.07%
-0.0101
Aprea Therapeutics Inc stock is traded at $0.9349, with a volume of 84,062.
It is down -1.07% in the last 24 hours and down -25.80% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$0.945
Open:
$0.95
24h Volume:
84,062
Relative Volume:
0.95
Market Cap:
$5.90M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.2343
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-11.80%
1M Performance:
-25.80%
6M Performance:
-51.31%
1Y Performance:
-73.44%
1-Day Range:
$0.9349
$0.978
1-Week Range:
$0.90
$1.1399
52-Week Range:
$0.90
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.9349 | 5.96M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus
Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com Nigeria
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com Nigeria
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com
Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in funding - marketscreener.com
Aprea Therapeutics raises $3.1 million in private placement - Investing.com
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics (Nasdaq: APRE) prices $3.1M private placement to extend cash runway into Q1 2027 - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) registers 219,242 shares under 2019 equity plan - Stock Titan
Why Aprea Therapeutics Inc. stock is seen as undervaluedMarket Weekly Review & Growth Focused Investment Plans - Newser
Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st
How Aprea Therapeutics Inc. stock performs in rising dollar environmentJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Head and Neck Cancer Therapeutics Market | Global Market Analysis Report2035 - Fact.MR
Why Aprea Therapeutics Inc. stock could rally in 20252025 Top Decliners & Stepwise Swing Trade Plans - moha.gov.vn
Is Aprea Therapeutics Inc a good long term investmentRSI Overbought/Oversold & Learn From the Strategies of Institutions - earlytimes.in
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Why Aprea Therapeutics Inc. stock could outperform in 2025July 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Aprea Therapeutics Inc. stock sustain free cash flow growthWatch List & Weekly Momentum Picks - newser.com
How supply chain issues affect Aprea Therapeutics Inc. stockEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Is Aprea Therapeutics Inc. stock a top momentum play2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Tools to assess Aprea Therapeutics Inc.’s risk profileQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Will Aprea Therapeutics Inc. stock outperform value stocks2025 Valuation Update & Weekly High Return Opportunities - newser.com
Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target - Barchart.com
Is Aprea Therapeutics Inc. stock attractive after correction2025 Big Picture & Fast Gaining Stock Reports - newser.com
Is Aprea Therapeutics Inc. stock poised for growthJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):